Aktuellt
SENASTE
Redeye views the collaboration with AstraZeneca in lymphoma as another quality stamp for BI-1206. Importantly, it improves BioInvent’s partnering potential, as a similar agreement is already in place with Merck, while AstraZeneca has a history of acquisitions in oncology.
LÄS MER
